James Leal - Sep 27, 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Signature
s/ David B. Berger, Attorney-in-Fact for James A. Leal
Stock symbol
TNDM
Transactions as of
Sep 27, 2021
Transactions value $
-$20,987
Form type
4
Date filed
9/29/2021, 04:46 PM
Previous filing
Sep 9, 2021
Next filing
Oct 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Options Exercise $85.9K +1.67K +44.44% $51.50 5.42K Sep 27, 2021 Direct F1
transaction TNDM Common Stock Options Exercise $19.6K +238 +4.39% $82.34 5.66K Sep 27, 2021 Direct F1
transaction TNDM Common Stock Sale -$79.3K -660 -11.67% $120.08 5K Sep 27, 2021 Direct F2, F3
transaction TNDM Common Stock Sale -$24.5K -201 -4.02% $121.99 4.8K Sep 27, 2021 Direct F2, F4
transaction TNDM Common Stock Sale -$128K -1.04K -21.77% $122.71 3.75K Sep 27, 2021 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Stock Option Options Exercise $85.9K +1.67K +6.25% $51.50 28.3K Sep 27, 2021 Common Stock 1.67K $51.50 Direct F6, F7
transaction TNDM Stock Option Options Exercise $19.6K +238 +3.22% $82.34 7.62K Sep 27, 2021 Common Stock 238 $82.34 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon exercise of a stock option award.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020.
F3 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $120.00 to $120.63. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F4 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $121.04 to $122.03. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F5 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $122.18 to $122.93. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F6 The options vested as to twenty-five (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F7 The expiration date for these options is 10 years from the date of grant.
F8 The options vested as to twenty-five (25%) of the underlying shares on 5/27/2021, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the 2013 Plan.